Cacna1g has also been identified as a genetic modifier of epilepsy in the Scn1a+/− mouse model of Dravet syndrome (Calhoun et al., 2017). Here, SCN1A is linked to encephalopathy, progressive, early-onset, with brain edema and/or leukoencephalopathy.